Italian regulators call for clearer costs and pricing

Italian regulators are calling for more transparency on drug costs and prices after an investigation into the vaccines market.

The report from the Italian Competition Authority was critical of the 20 billion euro market which it described as an “oligopoly of four multinational companies” and warned of a “deep lack of information on product costs and prices”.

The ICA, chaired by Professor Giovanni Pitruzzella, examined several issues from a competition viewpoint, some related to the general structure of the vaccine industry and the pharmaceutical sector, others more specific to the Italian market.